Literature DB >> 21731996

Effects of intrathecal midazolam in spinal anaesthesia: a prospective randomised case control study.

B K Shadangi1, R Garg, R Pandey, T Das.   

Abstract

INTRODUCTION: Subarachnoid block with local anaesthetics and adjuvants has been extensively used for surgery. Intrathecal midazolam produces antinociception and potentiates the effect of local anaesthetics. We compared intrathecal bupivacaine with and without midazolam to assess its effect on the duration of sensory block, motor block and pain relief.
METHODS: A total of 100 patients scheduled for elective lower abdominal, lower limb and gynaecological procedures were selected to participate in this prospective, randomised, double-blind study. Patients were randomly allocated into two groups for intrathecal drug administration. Group B received 3 mL 0.5 percent bupivacaine with 0.4 mL saline, and group BM received 3 mL 0.5 percent bupivacaine and 0.4 mL (2 mg) midazolam mixture. The onset, duration of sensory/motor block, time to first rescue analgesia and side effects were noted.
RESULTS: Demographic profile and duration of surgery were comparable between the two groups. The onset of sensory (4.8 versus 4.6 min) and motor block (5.9 versus 6 min) was also comparable between the groups. The duration of sensory blockade was prolonged in the midazolam group (90.8 versus 115.8 min, p-value is 0.001), while the duration of motor blockade was comparable (151.8 versus 151.3 min, p-value is 0.51). The duration of effective analgesia was significantly longer in the midazolam group compared to the control group (121.3 versus 221.1 min, p-value is 0.001). Sedation score was comparable in the two groups.
CONCLUSION: The addition of preservative-free midazolam to bupivacaine intrathecally resulted in prolonged postoperative analgesia without increasing motor block.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21731996

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  7 in total

1.  Efficacy of midazolam addition to local anesthetic in peribulbar block : Randomized controlled trial.

Authors:  M Ibrahim; E Gomaa
Journal:  Anaesthesist       Date:  2019-01-09       Impact factor: 1.041

2.  A randomised controlled trial comparing the effect of adjuvant intrathecal 2 mg midazolam to 20 micrograms fentanyl on postoperative pain for patients undergoing lower limb orthopaedic surgery under spinal anaesthesia.

Authors:  Francis Codero; Mung'ayi Vitalis; Sharif Thikra
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

3.  Comparative evaluation of intrathecal midazolam and low dose clonidine: efficacy, safety and duration of analgesia. A randomized, double blind, prospective clinical trial.

Authors:  Suchita A Joshi; Venkatesh V Khadke; Rajesh D Subhedar; Arun W Patil; Vijay M Motghare
Journal:  Indian J Pharmacol       Date:  2012-05       Impact factor: 1.200

4.  Intrathecal Midazolam as an Adjuvant in Pregnancy-Induced Hypertensive Patients Undergoing an Elective Caesarean Section: A Clinical Comparative Study.

Authors:  Ravichandra Dodawad; Sumalatha G B; Sandeep Pandarpurkar; Parashuram Jajee
Journal:  Anesth Pain Med       Date:  2016-07-26

5.  A study to compare the analgesic efficacy of intrathecal bupivacaine alone with intrathecal bupivacaine midazolam combination in patients undergoing elective infraumbilical surgery.

Authors:  Anirban Chattopadhyay; Souvik Maitra; Suvadeep Sen; Sulagna Bhattacharjee; Amitava Layek; Sugata Pal; Kakali Ghosh
Journal:  Anesthesiol Res Pract       Date:  2013-05-15

6.  Addition of low-dose ketamine to midazolam and low-dose bupivacaine improves hemodynamics and postoperative analgesia during spinal anesthesia for cesarean section.

Authors:  Ahmed Sobhy Basuni
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jan-Mar

7.  A novel approach to spinal anaesthesia to avoid aerosol-generating procedures in a patient with COVID-19 presenting for laser prostate surgery.

Authors:  Z Oon; C Ha
Journal:  Anaesth Rep       Date:  2020-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.